K. S. Legkova

K. S. Legkova

Auto-generated profile, based on publicly available information

K. S. Legkova

Bauman City Clinical Hospital № 29

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2022 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
EVE A Volchkova
E A Volchkova
KLK S Legkova
K S Legkova
TTT B Topchy
T B Topchy
Over the past two years, the entire medical community has taken up the fight against the new coronavirus infection. At the initial encounter with COVID-19, it seemed that this virus mainly affects the respiratory system. Still, with long-term observation, it turned out that the consequences of this disease can be much more severe and associated with lung damage and thromboembolic complications, and be a trigger for autoimmune diseases. According to the literature, after suffering COVID-19, some patients debuted systemic lupus erythematosus, hemolytic anemia, thrombocytopenia, developed GuillainBarr syndrome, vasculitis, and multiple sclerosis, and a case of autoimmune hepatitis (AIH) was described in foreign literature. AIH is a fairly rare disease, the prevalence of which in Europe is 1618 cases per 100 thousand inhabitants, affecting mainly women. It is known that chemicals and drugs (minocycline, diclofenac, methyldopa, infliximab, etanercept), viruses (HAV, HEV, EBV, HCV, CMV), environmental factors can serve as triggers of the autoimmune process in the liver. This article presents two clinical cases of AIH that developed after suffering a new coronavirus infection, which we consider as the initial provoking factor of autoimmune inflammation. Given the rarity of AIH, the description of new triggers is of clinical interest. It may be useful for doctors of different specialties since they faced drug-induced liver damage against the background of antiviral and immunobiological therapy. In the domestic literature, there have not yet been any publications devoted to the debut of AIH in adults after coronavirus infection.

4 November 2023 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
EVE. A. Volchkova
E. A. Volchkova
KLK. S. Legkova
K. S. Legkova
MAM. D. Ardatskaya
M. D. Ardatskaya
The number of patients complaining of indigestion is increasing every year. Made a significant contribution to this the COVID-19 pandemic, which has been going on for almost 3 years, led to this, the drugs used to treat the infection and its complications have a negative effect on the gastrointestinal tract, not to mention the most damaging effect of the virus. Against the backdrop of an increasing number of patients with indigestion as a result of COVID-19, it is important not to forget about other diseases that do not lie on the surface and do not always have typical manifestations. A relatively young disease, but increasingly common among patients with diarrhea, is microscopic colitis (MC). This article presents a clinical case of microscopic colitis of incomplete collagen type in combination with lactase deficiency. MC is a chronic inflammatory bowel disease of unknown etiology, characterized by chronic watery diarrhea, the absence of macroscopic signs of colon damage in the presence of specific pathomorphological changes. Based on the histological result, two main forms are distinguished: collagenous and lymphocytic colitis. According to the latest data presented in the European guidelines, the overall prevalence of MC is 119.4 cases per 100 thousand people, and the incidence is 11.4 cases per 100 thousand population per year. The progressive increase in the incidence, and even the prevalence of MC over patients with inflammatory bowel disease (IBD) in some countries in the group over 60 years of age, has led to an increase in clinical interest in this problem, improvement of diagnostic methods and revision of clinical guidelines in February 2021. Given the increase in the incidence of MC, the difficult diagnostic search for this diagnosis, age variation, and the description of clinical cases that differ from the average portraits of a “typical patient” with microscopic colitis are of clinical interest.

13 August 2026 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
EVE. A. Volchkova
E. A. Volchkova
KLK. S. Legkova
K. S. Legkova
LMLarisa Minushkina
Larisa Minushkina
YKYaroslav Kubkin
Yaroslav Kubkin
AKA. A. Keligova
A. A. Keligova
ДЗД. А. Затейщиков
Д. А. Затейщиков
Aim . To evaluate the contribution of polygenic risk scores to a short-term mortality prediction model in patients with dilated cardiomyopathy (DCM). M aterial and methods . The study included 137 patients with DCM. The mean age was 56,8±13,5 years; 115 (83,9%) were men. The median follow-up period was 17 [13; 22] months. During the follow-up period, 26 patients (19,0%) died. To identify predictors of short-term all-cause mortality, a classification tree model was constructed based on the chi-squared automatic interaction detection (CHAID) algorithm, supplemented by polygenic risk scores (PRS) for DCM and heart failure (HF). The model prognostic value was assessed using ROC analysis with area under the curve (AUC) calculation. R e sults . In the constructed model, the most significant predictors of short-term all-cause mortality were parenteral furosemide administration during the index hospitalization, high genetic risk according to the PGS005079 HF scale (cutoff value of 0,42), a ferritin level <101 ng/mL, and signs of systemic circulatory overload. The proportion of correctly classified cases was 81,0%, and the misclassification rate was 18,9%. According to ROC analysis, the model AUC was 0,786 (p<0,0001), sensitivity — 81,0%, and specificity — 61,4%. Conclusion . Short-term all-cause mortality prognosis in patients with dilated cardiomyopathy (DCM) is associated with the need for parenteral loop diuretics during the index hospitalization, decreased ferritin levels, a high genetic predisposition to heart failure (as assessed by the PGS005079 PGS), and signs of more severe heart failure decompensation involving the systemic circulation.